“We note that this approval came on schedule, in-line with our expectations, and that the market authorization of the first GnRH receptor antagonist should bode well for ObsEva’s lead candidate, linzagolix, which is also a member of this compound class and which is undergoing late-stage clinical testing for treatment of endometriosis and uterine fibroids. In the wake of the elagolix product approval, we reiterate our Buy rating and 12-month price target of $30.00 per share on OBSV. Orilissa pricing a pleasant surprise. We note that ObsEva management had previously guided towards the approximate cost of GnRH receptor antagonist therapy at roughly $15 per day—about $450 per month—and that the announced monthly cost of Orilissa at $845 appears to be comfortably above this level.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -1.9% and a 41.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
ObsEva SA has an analyst consensus of Strong Buy, with a price target consensus of $30.25.
Based on ObsEva SA’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $17.07 million. In comparison, last year the company had a GAAP net loss of $17.32 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.